trending Market Intelligence /marketintelligence/en/news-insights/trending/HsSKWglArfoulojavVtbhw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Apellis Pharmaceuticals raises $404.2M from stock offering


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Apellis Pharmaceuticals raises $404.2M from stock offering

Apellis Pharmaceuticals Inc. has raised $404.2 million in a previously announced public offering after underwriters fully exercised their overallotment option.

The Waltham, Mass.-based biopharmaceutical company sold 10,925,000 shares at $37 apiece, including the additional 1,425,000 shares in the underwriters' overallotment option.

Apellis develops treatments for autoimmune and inflammatory diseases.

Citigroup, J.P. Morgan and Evercore ISI were joint book-running managers for the offering, while Cantor Fitzgerald & Co. and Baird were lead managers.